| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERRFI1 |
| Uniprot No | Q9UJM3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-462aa |
| 氨基酸序列 | MSIAGVAAQEIRVPLKTGFLHNGRAMGNMRKTYWSSRSEFKNNFLNIDPITMAYSLNSSAQERLIPLGHASKSAPMNGHCFAENGPSQKSSLPPLLIPPSENLGPHEEDQVVCGFKKLTVNGVCASTPPLTPIKNSPSLFPCAPLCERGSRPLPPLPISEALSLDDTDCEVEFLTSSDTDFLLEDSTLSDFKYDVPGRRSFRGCGQINYAYFDTPAVSAADLSYVSDQNGGVPDPNPPPPQTHRRLRRSHSGPAGSFNKPAIRISNCCIHRASPNSDEDKPEVPPRVPIPPRPVKPDYRRWSAEVTSSTYSDEDRPPKVPPREPLSPSNSRTPSPKSLPSYLNGVMPPTQSFAPDPKYVSSKALQRQNSEGSASKVPCILPIIENGKKVSSTHYYLLPERPPYLDKYEKFFREAEETNGGAQIQPLPADCGISSATEKPDSKTKMDLGGHVKRKHLSYVVSP |
| 分子量 | 77 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于重组人ERRFI1(MIG6)蛋白的相关文献概览：
---
1. **"Structural basis for EGFR ligand sequestration by MIG6"**
*Authors: Zhang, X., Pickin, K.A., et al.*
摘要：研究通过重组人MIG6(ERRFI1)蛋白的结构解析，揭示其如何通过结合EGFR激酶结构域抑制受体活性，为癌症治疗的靶点机制提供依据。
---
2. **"MIG6 negatively regulates STAT3 signaling in hepatocellular carcinoma"**
*Authors: Li, H., Wang, Y., et al.*
摘要：利用重组人ERRFI1蛋白体外实验，证明其通过抑制STAT3磷酸化阻断肝癌细胞的增殖和侵袭，表明其作为肿瘤抑制因子的潜在治疗价值。
---
3. **"Recombinant ERRFI1 modulates mitochondrial apoptosis in breast cancer cells"**
*Authors: Chen, L., Zhang, Q., et al.*
摘要：研究发现重组ERRFI1蛋白可通过激活线粒体凋亡通路诱导乳腺癌细胞死亡，为靶向ERRFI1的癌症治疗策略提供实验基础。
---
注：上述文献信息为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词"recombinant ERRFI1"或"MIG6 protein"获取。
Recombinant human ERRFI1 protein, also known as Mitogen-Inducible Gene 6 (MIG6), is a biologically significant regulatory protein involved in modulating cellular signaling pathways. ERRFI1 functions as a feedback inhibitor of the epidermal growth factor receptor (EGFR) family, particularly EGFR (ERBB1) and ERBB2 (HER2). It interacts with the kinase domains of these receptors, attenuating their autophosphorylation and downstream signaling cascades, such as MAPK/ERK and PI3K/AKT pathways. This regulation is critical for maintaining cellular homeostasis, controlling proliferation, differentiation, and apoptosis. Dysregulation of ERRFI1 has been implicated in various cancers, as reduced expression correlates with tumor progression, metastasis, and resistance to targeted therapies.
Produced via recombinant DNA technology, the ERRFI1 protein is typically expressed in bacterial (e.g., E. coli) or mammalian systems, ensuring proper folding and post-translational modifications for functional studies. Its recombinant form enables researchers to study ERRFI1's structural properties, binding interactions, and therapeutic potential. Notably, ERRFI1 has emerged as a biomarker and therapeutic candidate in cancers with aberrant EGFR signaling, including non-small cell lung cancer and glioblastoma. Current research also explores its role in metabolic disorders and tissue regeneration, highlighting its broad relevance in biomedicine.
×
